Filinvest Development Corporation logo

Filinvest Development Corporation (FDC)

Market Open
7 Aug, 06:45
XPHS XPHS
3. 31
+0.01
+0.303%
- Market Cap
- P/E Ratio
3.2% Div Yield
508,000 Volume
- Eps
3.3
Previous Close
Add Transaction
Day Range
3.3 3.31
Year Range
3.3 4.97
Want to track FDC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

FDC trading today higher at ₱3.31, an increase of 0.303% from yesterday's close, completing a monthly decrease of -23.2019% or -₱1. Over the past 12 months, FDC stock lost -30.8977%.
FDC pays dividends to its shareholders, with the most recent payment made on Mar 07, 2026. The next estimated payment will be in In 6 months on Mar 07, 2027 for a total of ₱5.
The last earnings report, released on Nov 13, 2024, exceeded the consensus estimates by 0.4522%. On average, the company has surpassed earnings expectations by 0.3643%, based on the last three reports.
Filinvest Development Corporation has completed 2 stock splits, with the recent split occurring on Sep 14, 2011.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XNSE (INR).

FDC Chart

Filinvest Development Corporation (FDC) FAQ

What is the stock price today?

The current price is ₱3.31.

On which exchange is it traded?

Filinvest Development Corporation is listed on XPHS.

What is its stock symbol?

The ticker symbol is FDC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.2%.

What is its market cap?

As of today, no market cap data is available.

Has Filinvest Development Corporation ever had a stock split?

Filinvest Development Corporation had 2 splits and the recent split was on Sep 14, 2011.

Filinvest Development Corporation Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Ameya Ashok Chandavarkar CEO
XPHS Exchange
PHY247771496 ISIN
India Country
6,659 Employees
11 Feb 2026 Last Dividend
29 Apr 2004 Last Split
- IPO Date

Overview

FDC Limited is a prominent pharmaceutical company that operates both within India and on an international scale. Since its inception in 1936, the company has devoted itself to manufacturing and marketing a wide array of pharmaceutical products. Its diverse product portfolio caters to multiple therapeutic segments, making it a significant player in the pharmaceutical industry. Headquartered in Mumbai, India, FDC Limited has built a reputation for delivering specialized formulations that meet the growing healthcare needs of populations worldwide.

Products and Services

FDC Limited's product offerings span across various therapeutic categories and brands, tailored to address specific health conditions effectively. These include:

  • Anti-infective, Gastrointestinal, Ophthalmological, Vitamins/Minerals/Dietary Supplements, Cardiac, Anti-diabetes, Respiratory, Gynaecology, Dermatology, Analgesics, and Others: These specialized formulations are designed to treat a broad spectrum of conditions, ensuring comprehensive healthcare solutions.
  • Oral Rehydration Salts: A critical solution for dehydration and electrolyte imbalances, often resulting from diarrhoea and similar conditions. These products are essential in rehydration therapy.
  • Branded Formulations:
    • Zifi, Ziglim Plus 2, Vitcofol, Pyrimon DF, Zocon, Zoxan, Zathrin, Zipod, Amodep-AT, Zefu, Cotaryl, and Mycoderm
    • These brands are synonymous with quality and efficacy in their respective therapeutic areas, providing trusted options for healthcare professionals and patients alike.
  • Anti-oxidants, Balanced Energy Drinks, and Vitamins and Nutraceuticals:
    • Electral, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl, and Zefrich
    • FDC Limited offers a range of wellness products that include anti-oxidants, vitamins, and balanced energy drinks to support overall health and well-being.
  • Active Pharmaceutical Ingredients (APIs): Beyond finished dosage forms, the company also supplies various APIs, contributing to the manufacture of a wide range of pharmaceutical products globally.

Contact Information

Address: C/3, Skyvistas
Phone: 91 24 0255 4407